Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Molecular Pathology Research Laboratory, |
RCV001542234 | SCV001760902 | likely pathogenic | Deafness-lymphedema-leukemia syndrome; GATA2 deficiency with susceptibility to MDS/AML | 2021-07-06 | criteria provided, single submitter | curation | PS4_Moderate, PM1, PM2, PM5, PP3 |
St. |
RCV004785270 | SCV005402149 | pathogenic | GATA2 deficiency with susceptibility to MDS/AML | 2024-04-13 | criteria provided, single submitter | clinical testing | The GATA2 c.1078T>A (p.Trp360Arg) missense change is absent in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). The in silico tool REVEL predicts a deleterious effect on protein function, but this prediction has not been confirmed by functional studies. This variant has been reported in individuals with GATA2-deficiency (PMID: 25239263, 27577878, 28126493, 34893945). A variant affecting the same amino acid residue, p.Trp360Leu, was reported in a patient with GATA2-deficiency (PMID: 29146883). In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance. In summary, this variant meets criteria to be classified as pathogenic |
Labcorp Genetics |
RCV005225425 | SCV005863266 | uncertain significance | Deafness-lymphedema-leukemia syndrome; Monocytopenia with susceptibility to infections | 2024-12-02 | criteria provided, single submitter | clinical testing | This sequence change replaces tryptophan, which is neutral and slightly polar, with arginine, which is basic and polar, at codon 360 of the GATA2 protein (p.Trp360Arg). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with GATA2-related conditions (PMID: 25239263, 27577878, 28126493, 34387894, 34893945). ClinVar contains an entry for this variant (Variation ID: 1184247). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt GATA2 protein function with a positive predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |